Objective:

To explore alternative treatment options for glaucoma patients suffering from dry eye disease (DED), emphasizing the importance of addressing DED in this population.

Approach:

Key Findings:

• Glaucoma patients have a higher prevalence of DED, which can be exacerbated by glaucoma medications.
• SLT can lower intraocular pressure (IOP) by 20-30% in approximately 80% of patients.
• SRDD platforms may mitigate worsening DED symptoms.
• MIGS can reduce the need for topical drops, potentially improving adherence and reducing side effects.
• VR-based perimetry shows promise in improving tear film stability and test reliability, which is crucial for accurate visual field assessments.

Interpretation:

Innovative treatment and monitoring strategies are essential for managing glaucoma in patients with coexisting DED, as traditional methods may be inadequate, and ongoing research is necessary.

Limitations:

• Variability in test-retest results and defect detection in VR perimetry raises concerns about its widespread adoption, along with potential biases in the studies referenced.

Conclusion:

Addressing the unique needs of glaucoma patients with DED requires creative approaches, staying updated on advancements in treatment and diagnostic tools, and emphasizing patient education on DED management.

Sources:

• Clinical Ophthalmology
• Journal of Glaucoma
• Ophthalmic Physiology Optics
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.